Ovid Therapeutics (OVID) Other Non Operating Income (2022 - 2026)

Ovid Therapeutics has reported Other Non Operating Income for 5 years, with the latest figure at $858000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 62.94% year-over-year to $858000.0; the trailing twelve-month figure through Mar 2026 stood at $23.6 million (down 26.44% YoY), and the FY2025 full-year result was $25.0 million, down 29.41% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $858000.0, down from $22.0 million in the prior quarter.
• The five-year high for Other Non Operating Income was $29.0 million in Q2 2024, with the low at -$780000.0 in Q3 2024.
• Historically, Other Non Operating Income has averaged $4.1 million across 5 years, with a median of $858000.0 in 2026.
• The largest YoY upside for Other Non Operating Income was 1546.15% in 2024 against a maximum downside of 200.52% in 2024.
• Ovid Therapeutics' Other Non Operating Income stood at $668123.0 in 2022, then soared by 329.11% to $2.9 million in 2023, then tumbled by 48.76% to $1.5 million in 2024, then soared by 1394.69% to $22.0 million in 2025, then tumbled by 96.09% to $858000.0 in 2026.
• The last three Other Non Operating Income figures came in at $858000.0 (Q1 2026), $22.0 million (Q4 2025), and $365000.0 (Q3 2025), per Business Quant data.